Last evening, Enviro announced it had resolved a partially guaranteed rights issue of units of appro...
We expect Physitrack’s ongoing streamlining and consolidation efforts to begin bearing fruit in Q1 2...
Ahead of CapMan's Q1 2025 report due on 9 May, we revise our estimates to reflect expected fair valu...
Katalysen Ventures investerar i små onoterade nordeuropeiska bolag genom sitt investeringsramverk Ve...
Report out 24 April Q1e sales of SEK 53m, -1% y-o-y, EBIT SEK -0.
Fiskars is highly exposed to the US through Fiskars BA.
Q1'25e organic sales growth of 47% y-o-y Minor estimate changes FVR of SEK 30-45 reiterated What to...
Redeye comments on Lipum’s announcement of the finalized Clinical Study Report (CSR) for the phase I...
Slightly softer sales and outlook (-5% vs. ABGSCe in Q4) We cut '25e-'26e sales by 9-8%, EBIT 24-15%...
Redeye offers a preview of Polygien's Q1 results set to be released on April 24.
Redeye comments on Carasent’s Q1 report, showing solid ARR growth yet somewhat higher OPEX.
Incap had already anticipated a slow start for 2025, and now the entire EMS sector is holding its br...
Redeye expects Smart Eye’s Q1 report, due May 13, to show 12% y/y net sales growth and an EBITDA imp...
Redeye comments on SenzaGen’s expanded testing portfolio, introducing the EpiSensA method, which com...
Genetic Analysis AS (”Genetic Analysis” or ”the Company”) has developed the GA-map®, a platform for ...
